CVS Restores Coverage for Eli Lilly's Obesity Medications

Key Takeaways

• CVS Caremark will add Zepbound back to common commercial formularies as a preferred option effective October 1, 2026.
• Foundayo coverage blocks lift June 1, 2026 where plan sponsors approve the oral GLP-1.
• Lilly said all three major U.S. PBMs will cover its obesity portfolio; eligible commercial patients may pay as little as $25 per month with savings cards.
• Medicare Part D GLP-1 Bridge access at $50 per month is scheduled to begin July 1, 2026 for eligible beneficiaries through Dec 31, 2027.

What exactly did CVS Caremark announce for Zepbound?

CVS Health said Caremark will reintroduce Zepbound on its most common commercial formularies as an additional preferred option beginning October 1, 2026. The company framed the change as part of broader efforts to secure more affordable GLP-1 pricing for plan sponsors that elect weight-management coverage. Details are in the May 28, 2026 PR Newswire release.

Plan sponsors that use Caremark template formularies still control customization. European market-access teams watching U.S. spillover should note that this is a U.S. PBM template decision, not an EMA or NICE action.

How does Foundayo fit the same announcement?

Effective June 1, 2026, Caremark said it will remove the new-to-market block on Foundayo where plans approve coverage. Lilly’s companion release said Foundayo template coverage begins June 1 and that current Zepbound patients keep continuity while broader template access expands by October 1. See Lilly’s PR Newswire statement.

Foundayo is Lilly’s once-daily oral non-peptide GLP-1 receptor agonist. Company materials state FDA approved it for adults with obesity or overweight with weight-related problems alongside diet and activity. Oral dosing without food or water restrictions is a differentiation claim versus injectables, but outcomes and adherence still need real-world proof.

What does FDA labeling say about Zepbound?

According to the FDA Zepbound label, tirzepatide is a dual GIP and GLP-1 receptor agonist indicated with diet and exercise to reduce excess body weight long term and to treat moderate to severe obstructive sleep apnea in adults with obesity. A boxed warning covers thyroid C-cell tumor risk observed in rats; the drug is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.

• Initial U.S. approval year: 2022
• Class: GIP/GLP-1 receptor agonist (tirzepatide)
• Coadministration with other tirzepatide or GLP-1 products is not recommended per label limitations

What about Medicare Part D pricing signals?

Lilly said eligible Medicare Part D beneficiaries may pay $50 per month for obesity medicines beginning July 1, 2026 through the Medicare GLP-1 Bridge program running to December 31, 2027. Separately, CMS operates Medicaid and Medicare demonstration pathways that can change net pricing dynamics; teams should verify member-level eligibility rather than assume blanket coverage.

Commercial coupons at about $25 per month for eligible insured patients are manufacturer programs, not Caremark guarantees. Out-of-pocket math still depends on deductible status and prior authorization.

How does this reshape competitive dynamics versus Wegovy?

Caremark had previously preferred Novo Nordisk’s Wegovy on many standard plans after a 2025 contracting cycle. Restoring Zepbound as co-preferred puts Lilly and Novo on more equal formulary footing for employers that adopt the template. Continuity protections for members already on semaglutide remain a practical constraint on rapid switching.

For EU-based HQ teams, the U.S. PBM reset affects global revenue concentration even when European HTA outcomes differ. Forecast models should re-run U.S. volume with dual preferred status and test downside if large self-funded employers opt out of obesity coverage entirely.

What remains unproven after the formulary headline?

Net prices after rebates are not public in the press releases. Neither CVS nor Lilly disclosed the exact concession that restored preferred status. Persistence, dose titration success, and comparative weight-loss durability between injectable tirzepatide and oral orforglipron in routine care remain evidence gaps beyond pivotal trials.

Related NovaPharma coverage

• FDA Zepbound OSA approval
• Foundayo FDA approval coverage
• Kailera obesity shot trial

How should evidence teams document claims?

Keep a living evidence log that maps each numeric claim to a dated primary URL, captures the exact denominator, and notes whether the figure is intent-to-treat, per-protocol, or sponsor-described. When a press release and a peer-reviewed abstract diverge, privilege the peer-reviewed or labeling source and delete the weaker claim from customer-facing copy.

Internal reviewers should reject any draft that cites competitor newsrooms as hyperlinks, invents savings percentages, or treats a PDUFA goal date as an approval. Those process rules protect YMYL credibility as much as the underlying science.

Frequently Asked Questions

Primary Sources

1. PR Newswire: CVS Caremark formulary update
2. PR Newswire: Lilly Foundayo and Zepbound coverage
3. FDA label: Zepbound
4. CMS: GENEROUS Medicaid drug pricing model